Main Menu

The discovery of the S1-4-A09 antibody and its A80P derivative from a survivor of Ebola virus disease represents a significant advancement in the development of therapeutics against Ebola virus. These antibodies, isolated using innovative techniques, demonstrate potent antiviral activities in vitro and have shown improved stability and manufacturing feasibility compared to existing antibodies.

The technology offers a novel and efficient method for inducing targeted DNA recombination using a tripartite fusion protein, LFn-NLS-Cre, in combination with anthrax toxin protective antigen (PA). This system enables precise genetic manipulation in cells carrying a gene flanked by loxP sites, allowing for specific recombination events.

The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions.

The technology pertains to a novel multivalent peptide tolerogen designed for the therapeutic treatment of Multiple Sclerosis (MS), a condition where the immune system erroneously attacks the central nervous system. This advanced therapeutic strategy involves a fusion-peptide composed of myelin oligodendrocyte glycoprotein (MOG), myelin-basic protein (MBP), and myelin proteolipid protein (PLP), along with myelin-associated glycoprotein (MAG).

The technology involves the adaptation of CHO-DG44 cells to ActiCHO P medium, improving their doubling time and suitability for generating stable cell lines for GMP purposes. These stable cell lines are designed for expressing the RSV F protein stabilized in the prefusion conformation, including the DS-Cav1 mutation, developed by the Vaccine Research Center.

The PSY2 Bovidae aurbeta/gamma shuttle vector represents a pioneering technology in the field of genetic engineering. This innovative vector system has been designed for use in Bovidae species, potentially offering a novel approach to gene delivery and manipulation. It leverages a dual-functionality mechanism that could enable both autonomous replication and the precise insertion of genetic material.

The "Adjuvant pro-drug platform for gene delivery and spatiotemporal control over immune activation" is a groundbreaking technology that addresses the limitations of DNA and RNA-based vaccines by providing spatiotemporal control over immune activation. This platform utilizes a cationic polymer with pro-drug Toll-like receptor-7/8 agonists attached, allowing for the complexation of RNA and DNA to form nanoparticles for in vivo administration.

This technology presents a novel prime-boost vaccine strategy using recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors to protect against lentiviral infections, particularly HIV. The approach involves different prime-boost combinations with LCMV vectors expressing HIV proteins, demonstrating efficacy in eliciting immune responses.

The Thermo-responsive adjuvant scaffolds (TRAS) technology offers a groundbreaking approach to vaccine delivery and immunotherapy. TRAS utilizes carriers consisting of Toll-like receptor agonists (TLRa) attached to linear polymer carriers. These carriers are designed to assemble into particles in vivo, addressing the limitations of current particle-based delivery platforms.

The discovery of antimicrobial-resistant Staphylococcus aureus strains NR-46192 and NR-46201 represents a significant advancement in the study and treatment of antibiotic resistance. Isolated from patient samples and resistant to multiple antibiotics, these strains offer valuable insights into the mechanisms of resistance and provide a critical resource for antimicrobial research and testing.